Hyderabad-based Suven Life Sciences Limited today said it was granted four product patents, one each from Australia, Canada, Korea and New Zealand corresponding to the new chemical entities (NCEs) related to neurodegenerative diseases.
These patents include the class of selective 5-HT compounds (amino acids present in brain) discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with Alzheimer's, attention deficient hyperactivity disorder, Huntingdon disease, Parkinson an Schizophrenia, the company said in a press release.
It has about 12 internally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting CNS (Central Nervous System) disorders, according to the statement..
The company had reported a net profit of Rs 15.52 crore with total revenues at Rs 203.82 crore last year. Most of its revenues come from contract manufacturing and other services. The company's shares are trading at Rs 16.46, up 7.3% or by Rs 1.12 on Bombay Stock Exchange during Thursday afternoon.
Top Section
Explore Business Standard